Elicit: CD80/CD86 Blockade and T-Cell Dynamics

CD80/CD86 Blockade and T-Cell Dynamics

How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?

Abstract

CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics. CD8+ T-cell subsets remain relatively resistant to these effects, indicating lesser reliance on CD28 costimulation. The effects are reversible after treatment discontinuation, with T-cell populations returning to baseline within 6 months, indicating that abatacept maintains an altered immune state through continuous pharmacological inhibition rather than inducing permanent tolerance.

Effects on regulatory T cells are context-dependent and paradoxical: in rheumatoid arthritis, abatacept increases Treg numbers through reduced apoptosis but diminishes their suppressive function because CD80/CD86 blockade on responder T cells reduces susceptibility to Treg-mediated suppression, while in multiple sclerosis, memory Treg frequencies decrease due to their dependence on ongoing costimulation. Clinical translation of these immunological effects varies substantially by disease, with robust benefits observed in GVHD prevention where transient early suppression of donor T-cell activation is sufficient, sustained benefits in established rheumatoid arthritis with high baseline T-cell activation, but no clinical improvement in mild atopic asthma despite similar shifts in T-cell populations. This heterogeneity suggests that costimulation blockade is most effective when CD28-dependent T-cell responses drive disease pathology and baseline immune activation is high.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Results

Characteristics of Included Studies

... (additional studies omitted for brevity)

Effects on T-cell Activation

Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls, with effects concentrated in effector memory populations. In multiple sclerosis, abatacept decreased the proportion of CD38+ and ICOS+ activated cells within both T follicular helper (Tfh) and regulatory T cell populations.

The activation changes were selective for certain T-cell populations. CD4+ T cells were consistently more affected than CD8+ T cells across studies. In type 1 diabetes, CD4+ conventional and regulatory subsets showed altered frequencies while CD8+ subsets remained relatively resistant, indicating lesser reliance on CD28-mediated costimulation in CD8+ cells.

Effects on T-cell Subset Distribution

Abatacept consistently shifted CD4+ T-cell compartments toward naive phenotypes while reducing memory populations. In type 1 diabetes, abatacept treatment significantly reduced central memory CD4+ T cells while increasing naive CD4+ T cells, with the reduction driven by decreased absolute numbers in circulation.

Effects on Regulatory T Cells and Tolerance

Abatacept’s effects on regulatory T cells varied by subset and assay. In rheumatoid arthritis, total Treg numbers increased after treatment initiation, but functional suppression assays revealed diminished capacity to suppress responder T-cell proliferation.

Temporal Dynamics of Effects

The onset and kinetics of T-cell effects varied by subset. In GVHD prevention, significant inhibition of CD4+ T-cell proliferation was evident by day +28, but similar levels of activation were observed in treated and control cohorts after day +100, indicating transient effects limited to the period of drug exposure.

Mechanistic Insights into Activation vs. Tolerance

Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes. Transcriptional profiling in multiple sclerosis revealed that abatacept decreased expression of genes regulating cell cycle and chromatin dynamics during proliferation.

Study Quality and Limitations

Several factors affect interpretation of these findings across studies. Sample size limitations were notable, particularly for immunological endpoints.

Synthesis

The evidence reveals a consistent pattern: abatacept reduces T-cell activation markers and shifts CD4+ compartments toward naive phenotypes while showing limited effects on CD8+ cells. However, the relationship between these immunological changes and clinical outcomes varies substantially across diseases, warranting careful examination of why similar T-cell effects produce different therapeutic results.

References

  1. S. Glatigny et al., (2019). Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance. Journal of Immunology
  2. M. Bonelli et al., (2016). Abatacept treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Rheumatology
  3. J. Kremer et al., (2006). Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. Annals of Internal Medicine